607TiP - TransSCOT – translational research based on the Short Course Oncology Therapy (SCOT) cohort

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Gastrointestinal Cancers
Presenter Bodil Elisabeth Engelmann
Citation Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370
Authors B.E. Engelmann1, T. Iveson2, E. Høgdall3, N.H. Holländer4
  • 1Department Of Clinical Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 2Medical Oncology, Southampton General Hospital Southampton University Hospitals NHS Trust, SO16 6YD - Southampton/GB
  • 3Department Of Pathology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 4Oncology, Zealand University Hospital, 4700 Næstved - Naestved/DK

Abstract

Background

The Short Course Oncology Therapy (SCOT) study of adjuvant chemotherapy in colorectal cancer aims to ascertain whether 3 months of treatment is as efficacious as 6 months. The study is designed to assess clinical, quality of life and cost-effectiveness outcomes. However, the unique patient material in the SCOT study could help answer questions in the following translational research areas: · Molecular tumour characteristics with prognostic significance in colorectal cancer · Molecular characteristics with predictive significance regarding treatment efficacy and toxicities of 5-FU and oxaliplatin adjuvant treatment in colorectal cancer · Identification of circulating prognostic markers that could be used in personalized follow-up after adjuvant treatment · Identification of genes that could be useful as targets for personalized adjuvant chemotherapy in high-risk patients

Trial design

SCOT recruited patients from 2008 to 2013. 6144 patients were randomised at 243 sites in 6 countries; 311 patients in Denmark. For TransSCOT, all patients that have consented to participation in SCOT are asked for further blood samples and permission to access tumour specimen. TransSCOT is currently recruiting in the UK, Sweden and Denmark. Tumour blocks from 2833 TransSCOT participants are collected in Glasgow, UK, and blood samples from 2964 participants in Oxford, UK, whereas tumour specimens and blood samples from the Danish TransSCOT cohort are collected in the Danish Cancer Biobank (DCB) at Herlev Hospital. Tissue slides and tissue microarrays (TMAs) are prepared for immunohistochemical staining and in-situ hybridization. DNA extraction from blood samples and corresponding tumour tissue is performed for next generation sequencing (NGS). Furthermore, miRNA are extracted in expression arrays. Design of TMAs, panels of markers for NGS and miRNAs of interest are currently defined in the TransSCOT Biorepository Management Group.

Clinical trial identification

NCT00749450

Legal entity responsible for the study

Department of Oncology, Næstved Hospital, Næstved, Denmark

Funding

Zealand Healthcare Regiońs Foundation for Health Science Research

Disclosure

All authors have declared no conflicts of interest.